124
- Virdis A, Bacca A, Colucci R, Duranti E, Fornai M, Materazzi G, et al. Endothelial dysfunc-
tion in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative
stress generation. Hypertension. 2013;62(2):337–44. - Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, et al. Resistant arterial hyperten-
sion is associated with higher blood levels of complement C3 and C-reactive protein. J Clin
Hypertens (Greenwich, Conn). 2008;10(9):677–83. - Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, Casale R, et al. C-reactive protein:
interaction with the vascular endothelium and possible role in human atherosclerosis. Curr
Pharm Des. 2007;13(16):1631–45. - Andrikou I, Tsioufis C, Dimitriadis K, Syrseloudis D, Valenti P, Almiroudi M, et al. Similar
levels of low-grade inflammation and arterial stiffness in masked and white-coat hyper-
tension: comparisons with sustained hypertension and normotension. Blood Press Monit.
2011;16(5):218–23. - Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibi-
tor of metalloproteinase-1 system on large arterial stiffness in patients with essential hyper-
tension. Hypertens Res Off J Jpn Soc Hypertens. 2007;30(10):959–63. - Dorr O, Liebetrau C, Mollmann H, Mahfoud F, Ewen S, Gaede L, et al. Beneficial effects of
renal sympathetic denervation on cardiovascular inflammation and remodeling in essential
hypertension. Clin Res Cardiol Off J German Cardiac Soc. 2015;104(2):175–84. - Eikelis N, Hering D, Marusic P, Sari C, Walton A, Phillips S, et al. The effect of renal dener-
vation on endothelial function and inflammatory markers in patients with resistant hyperten-
sion. Int J Cardiol. 2015;188:96–8. - Xiao L, Kirabo A, Wu J, Saleh MA, Zhu L, Wang F, et al. Renal denervation prevents immune
cell activation and renal inflammation in angiotensin II-induced hypertension. Circ Res.
2015;117(6):547–57. - El Rouby N, Cooper-DeHoff RM. Genetics of resistant hypertension: a novel pharmacoge-
nomics phenotype. Curr Hypertens Rep. 2015;17(9):583. - Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hyper-
tension. Pharmacol Res. 2004;49(4):351–6. - Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med.
2012;44(Suppl 1):S17–22. - Tabara Y, Kohara K, Miki T. Hunting for genes for hypertension: the millennium genome
project for hypertension. Hypertens Res Off J Jpn Soc Hypertens. 2012;35(6):567–73. - Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, et al. Gene
variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting
enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol.
2011;30(8):555–64. - Doris PA. Hypertension genetics, single nucleotide polymorphisms, and the common
disease:common variant hypothesis. Hypertension. 2002;39(2 Pt 2):323–31. - Turner ST, Boerwinkle E, O’Connell JR, Bailey KR, Gong Y, Chapman AB, et al. Genomic
association analysis of common variants influencing antihypertensive response to hydrochlo-
rothiazide. Hypertension. 2013;62(2):391–7. - Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, et al.
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic
evaluation of antihypertensive responses (PEAR) study. Am Heart J. 2009;157(3):442–9. - Fontana V, McDonough CW, Gong Y, El Rouby NM, Sa AC, Taylor KD, et al. Large-scale
gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc.
2014;3(6):e001398. - Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and adverse health
outcome associations with treatment resistant hypertension in GenHAT. Int J Hypertens.
2013;2013:578578. - Hirawa N, Fujiwara A, Umemura S. ATP2B1 and blood pressure: from associations to patho-
physiology. Curr Opin Nephrol Hypertens. 2013;22(2):177–84.
A. Burlacu and A. Covic